Detalles de la búsqueda
1.
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Clin Pharmacokinet
; 57(1): 87-102, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28508936
Resultados
1 -
1
de 1
1
Próxima >
>>